EUVIMEDEUVIMED entdecken
Crossref

The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma

Megan Parker, Austin Carmichael, Antolin Serrano-Farias, Melanie Alfonzo Horowitz, Kristin J Redmond, Calixto-Hope G Lucas, Debraj Mukherjee, Youssef Comair, Chetan Bettegowda, Jordina Rincon-Torroella

Neurosurgical Focus · 2025

DOI: 10.3171/2025.5.focus25350 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Focus, 2025. Verfasst von Megan Parker und 9 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, DNA Repair Enzymes, DNA Modification Methylases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Although MGMT promoter methylation, gross-total resection (GTR), and adjuvant chemoradiation therapy are known to independently improve clinical outcomes for patients with glioblastoma (GBM), their combined influence remains unclear. In the present study, the authors investigated the complementary role of these factors in GBM prognosis. METHODS The 2022 National Cancer Database was queried for individuals with histologically confirmed IDH-wildtype GBM WHO grade 4 and available MGMT promoter methylation status data. Demographic, clinical, and treatment-related variables were analyzed. Kaplan-Meier survival and multivariate Cox proportional hazards analyses were conducted, stratified by MGMT promoter methylation and chemoradiation therapy status. RESULTS A total of 27,858 patients were included in the analysis. Chemotherapy, radiation therapy, and MGMT promoter methylation status were independently associated with improved survival in the overall cohort (p < 0.001). In Kaplan-Meier analysis, MGMT promoter methylation was associated with improved overall survival for individuals who received standard chemoradiation therapy (p < 0.001) but not for individuals who did not receive chemoradiation therapy (p = 0.649). In the overall cohort, GTR was associated with a 40% improvement in overall survival relative to excisional biopsy (HR 0.633 [95% CI 0.52–0.77], p < 0.001) in multivariate analysis. In patients with MGMT promoter–methylated tumors, GTR was associated with a 70% (HR 0.30 [95% CI 0.12–0.71], p = 0.007) improvement in overall survival compared with excisional biopsy in those who did not receive chemoradiation therapy, but GTR did not significantly improve survival in those who received chemoradiation therapy (HR 0.97 [95% CI 0.54–1.73], p = 0.912). For patients with MGMT promoter–unmethylated tumors, GTR was associated with improved overall survival for both those who received chemoradiation therapy (HR 0.48 [95% CI 0.33–0.70], p < 0.001) and those who did not (HR 0.50 [95% CI 0.28–0.89], p = 0.018). CONCLUSIONS In this large registry study, the authors demonstrated that maximizing the extent of resection improves overall survival, especially for individuals with MGMT unmethylated GBM or those not receiving chemoradiation therapy. However, the impact of gross-total resection requires further investigation in patients with MGMT promoter–methylated GBM who receive adjuvant therapy. These findings support future studies exploring new diagnostic techniques for preoperative evaluation of MGMT methylation to aid surgical planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsDNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsDNA MethylationChemoradiotherapyHumansFemaleMaleMiddle AgedPromoter Regions, GeneticIsocitrate DehydrogenaseAgedAdultCohort StudiesNeurosurgical ProceduresRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

MGMTNCDBNational Cancer Databasechemoradiationextent of resectionglioblastomasurvival

Substanzen

DNA Repair EnzymesDNA Modification MethylasesTumor Suppressor ProteinsMGMT protein, humanIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • 1Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore.
  • 2Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore; and.
  • 3Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Zitieren

APA

Parker, M., Carmichael, A., Serrano-Farias, A., Alfonzo Horowitz, M., Redmond, K. J., Lucas, C. G., Mukherjee, D., Comair, Y., Bettegowda, C., & Rincon-Torroella, J. (2025). The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma. Neurosurgical Focus. https://doi.org/10.3171/2025.5.focus25350

Vancouver

Parker M, Carmichael A, Serrano-Farias A, Alfonzo Horowitz M, Redmond KJ, Lucas CG, et al. The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma. Neurosurgical Focus. 2025. doi:10.3171/2025.5.focus25350

BibTeX
@article{Parker2025,
  author = {Parker, Megan and Carmichael, Austin and Serrano-Farias, Antolin and Alfonzo Horowitz, Melanie and Redmond, Kristin J and Lucas, Calixto-Hope G and Mukherjee, Debraj and Comair, Youssef and Bettegowda, Chetan and Rincon-Torroella, Jordina},
  title = {The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma},
  journal = {Neurosurgical Focus},
  year = {2025},
  doi = {10.3171/2025.5.focus25350}
}
Kostenlos starten →